Mitsune Tanimoto

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

Fumihiko Hayakawa, Masayuki Towatari, Hitoshi Kiyoi et al. · Oncogene · 2000 · 576 citations

Life Sciences, Cell Biology, Genetics +8

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura et al. · Clinical Cancer Research · 2005 · 496 citations · Full text

Medicine, Genetics, Oncology +15

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura, Takashi Ishida, Kiyohiko Hatake et al. · Journal of Clinical Oncology · 2014 · 361 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007

Yoshihiko Segawa, Katsuyuki Kiura, Nagio Takigawa et al. · Journal of Clinical Oncology · 2010 · 255 citations · Full text

Medicine, Oncology, Pharmacotherapy +12